Seeking Alpha
11 Aug 2026, 06:15 UTC · 14w ago
Protara Therapeutics: Orphan Drug Indications Drive A Heavily Undervalued Pipeline
Impact · against what's priced in
Protara Therapeutics shows significant upside potential based on its orphan drug pipeline and a fair value estimate of $9.96. While the IV Choline Chloride candidate offers a high-revenue path, the long timeline to 2026 data and competition for TARA-002 act as primary drags on immediate valuation.
- PRTA+0.50
No priced-in read yet
- In context
The company's risk-adjusted fair value of $9.96 suggests the current $4 price heavily undervalues its pipeline, specifically the revenue potential of IV Choline Chloride and orphan drug indications for TARA-002.
Read from the article alone





